Loading…
Employees: 1,482
Size Qingdao Kingking Applied Chemistry (002094.SZ) is a China Consumer Staples company (Household/Personal Care) with a market value of $464M, the 4043rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.48 on 6 Nov 2026.
Performance Over six months the shares fell 24.8%, against -17.0% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 7.1% over the last twelve months (peer median +7.0%); the operating margin is 4.3% (peer median 8.8%).
Valuation It trades at 2.1× enterprise value to sales against a peer median of 1.6× (7th most expensive of 21).
Capital Return on invested capital runs 2.3 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.69B | CN¥1.67B | CN¥1.79B | CN¥2.50B | CN¥2.95B |
| Revenue growth | — | -6% | -29% | -15% | — |
| Gross profit | CN¥298M | CN¥293M | CN¥320M | CN¥222M | CN¥215M |
| EBITDA | CN¥112M | CN¥107M | CN¥112M | CN¥34.9M | -CN¥331M |
| Net income | -CN¥14.0M | CN¥21.2M | CN¥35.1M | CN¥10.4M | -CN¥809M |
| Free cash flow | -CN¥117M | CN¥7.04M | CN¥20.8M | CN¥178M | CN¥70.3M |
| Capital expenditure | CN¥163M | CN¥155M | CN¥23.3M | CN¥2.48M | CN¥37.3M |
| Total debt | CN¥1.55B | CN¥1.41B | CN¥1.36B | CN¥1.47B | CN¥1.39B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002094.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.4% | -10.0% | 9th highest of 21 |
| 6-month return | -24.8% | -17.0% | 5th lowest of 21 |
| Distance from 52-week high | -50.2% | -34.9% | 2nd lowest of 21 |
| Revenue growth (TTM) | -7.1% | +7.0% | 4th lowest of 21 |
| Operating margin | 4.3% | 8.8% | 6th lowest of 21 |
| EV / Sales | 2.1× | 1.6× | 7th most expensive of 21 |
| ROIC minus cost of capital | -2.3 pp | +4.9 pp | 6th lowest of 21 |
| EV / EBITDA | 32.1× | 10.8× | 2nd most expensive of 11 |
| Net debt / EBITDA | 4.4× | -1.3× | most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qingdao Kingking Applied Chemistry 002094.SZ | China | $464M | -25% | -7% | 4% | 2.1× | n/a | n/a |
| Tianjin Yiyi Hygiene Products 001206.SZ | China | $448M | -15% | -8% | 9% | 1.5× | 2.5% | +6.3% |
| Lafang China 603630.SS | China | $445M | -20% | -3% | 2% | 2.4× | n/a | n/a |
| Jinglv Environment Science & Technology 001230.SZ | China | $415M | -22% | +28% | 11% | 1.4× | n/a | n/a |
| Liuzhou Liangmianzhen 600249.SS | China | $398M | -19% | -11% | -7% | 1.3× | n/a | n/a |
| Bajaj Consumer Care BAJAJCON.NS | India | $551M | -24% | +29% | 22% | 3.6× | 14.6% | +5.0% |
| McBride MCB.L | United Kingdom | $386M | +11% | +1% | 6% | 0.4× | -0.9% | +6.5% |
| PZ Cussons PZC.L | United Kingdom | $566M | +30% | +5% | 11% | 0.9× | -1.7% | -2.1% |
| Shandong Hiking International 600735.SS | China | $338M | -29% | -11% | -2% | 1.4× | -5.7% | +1.5% |
| Hangzhou Coco Healthcare Products 301009.SZ | China | $332M | -26% | +7% | 0% | 1.6× | n/a | n/a |
| Milbon 4919.T | Japan | $669M | +30% | +6% | 13% | 1.7× | -3.1% | +8.2% |
| Yuen Foong Yu Consumer Products 6790.TW | Taiwan | $301M | -7% | -4% | 13% | 0.9× | -14.9% | +1.0% |
| Hangzhou Haoyue Personal Care 605009.SS | China | $750M | -19% | +10% | 6% | 1.5× | 4.7% | +7.7% |
| Jyothy Labs JYOTHYLAB.NS | India | $773M | -23% | +5% | 8% | 2.2× | 35.0% | +8.9% |
| Cosmecca Korea 241710.KS | South Korea | $798M | +25% | +44% | 13% | 1.7× | -5.9% | +13.6% |
| Galaxy Surfactants GALAXYSURF.NS | India | $819M | +13% | +30% | 9% | 1.2× | 18.0% | +13.7% |
| Runben Biotechnology 603193.SS | China | $940M | -33% | +13% | 21% | 2.8× | 1.7% | +28.4% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $944M | +15% | +10% | 11% | 2.7× | 4.3% | +10.8% |
| Tongling Jieya Biologic Technology 301108.SZ | China | $961M | +47% | +54% | 7% | 6.2× | n/a | n/a |
| Noevir 4928.T | Japan | $977M | +3% | +1% | 16% | 2.1× | -4.8% | +4.5% |
| SYoung 300740.SZ | China | $1.00B | -37% | +14% | 3% | 1.3× | 18.1% | +6.1% |